Triplet regimen is well tolerated by patients with AML but does not improve survival outcomes
MD Anderson Research Highlight April 17, 2025
Patients with acute myeloid leukemia (AML) who have high-risk genetic changes and those with relapsed disease have poor outcomes with available treatment options. Magrolimab is a novel monoclonal antibody drug that targets a protein on leukemia cells that helps them evade immune responses. In a Phase Ib/II clinical trial led by .,and .,magrolimab was studied in combination with azacitidine and venetoclax in patients with newly diagnosed, high-risk AML who were not eligible for intensive therapy and in patients with relapsed or refractory AML. In the newly diagnosed cohort, the study also included patients with a TP53 mutation, which is associated with poor prognoses. The triplet regimen was well tolerated, and responses and survival outcomes were consistent with currently available regimens. Research into genetic factors suggested specific resistance patterns and signs of leukemia regrowth after treatment. While the regimen was safe overall, the results indicate it may not significantly improve survival outcomes. Learn more in .
This trial highlights the powerful collaboration between our leukemia clinical trials team and cutting-edge translational labs that enables us to learn valuable information to develop future targets and agents even if trial results do not suggest improved outcomes.